SCHEMBL666201

SCHEMBL666201

Nc1ncc(-c2cnn(C3CCNCC3)c2)c2c(Cl)c(-c3cccc4cnccc34)oc12

nearest known ligand 0.54

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
MAP3K7 O43318 5/20 0.54
TAB1 Q15750 5/20 0.54
AURKB Q96GD4 2/20 0.54
MAP4K3 Q8IVH8 4/20 0.51
MET P08581 11/20 0.47
KDR P35968 1/20 0.46
KCNH2 Q12809 2/20 0.44
GRK2 P25098 2/20 0.43
GRK5 P34947 2/20 0.43
FLT3 P36888 1/20 0.43
MST1R Q04912 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10217379 0.84 MAP3K7 (0.71) MAP3K7TAB1AURKBMAP4K3MET
SCHEMBL660166 0.84 MAP3K7 (0.73) MAP3K7TAB1AURKBMAP4K3KDR
Hydrochloric Acid SCHEMBL660607 0.83 MAP3K7 (0.70) MAP3K7TAB1AURKBMAP4K3MET
SCHEMBL10217380 0.83 MAP3K7 (0.66) MAP3K7TAB1AURKBMAP4K3MET
Hydrochloric Acid SCHEMBL659954 0.82 MAP3K7 (0.65) MAP3K7TAB1AURKBMAP4K3MET
SCHEMBL31134334 0.80 CYP1A2 (0.57) MAP3K7TAB1MAP4K3
SCHEMBL660838 0.80 MAP3K7 (0.58) MAP3K7TAB1AURKBMAP4K3MET
SCHEMBL10270699 0.76 MAP3K7 (0.51) MAP3K7TAB1AURKBMAP4K3MET
SCHEMBL10270737 0.76 GRK5 (0.59) MAP3K7TAB1AURKBMAP4K3MET
Hydrochloric Acid SCHEMBL661270 0.76 MAP3K7 (0.51) MAP3K7TAB1AURKBMAP4K3MET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8378104-B2 7-aminofuropyridine derivatives OSI Pharmaceuticals, LLC (US) 2013-02-19 US disclosed
US-8378104-B2 7-aminofuropyridine derivatives OSI Pharmaceuticals, LLC (US) 2013-02-19 US disclosed
US-8378104-B2 7-aminofuropyridine derivatives OSI Pharmaceuticals, LLC (US) 2013-02-19 US disclosed
US-20120046267-A1 7-AMINOFUROPYRIDINE DERIVATIVES OSI PHARMACEUTICALS, INC. 2012-02-23 US disclosed
US-20120046267-A1 7-AMINOFUROPYRIDINE DERIVATIVES OSI PHARMACEUTICALS, INC. 2012-02-23 US disclosed
US-20120046267-A1 7-AMINOFUROPYRIDINE DERIVATIVES OSI PHARMACEUTICALS, INC. 2012-02-23 US disclosed
WO-2011100502-A1 7-AMINOFUROPYRIDINE DERIVATIVES OSI Pharmaceuticals, LLC (US) 2011-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046267-A1 7-AMINOFUROPYRIDINE DERIVATIVES MAP3K5, STK17A, MAPKAPK5 MAP3K7 5/4885TAB1 4/4885AURKB 89/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.